Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: DISCOVER study.
Oreja-Guevara C, Meca-Lallana JE, Díaz-Díaz J, Ara JR, Hernández Pérez MÁ, Gracia Gil J, Alonso Torres AM, Pilo de la Fuente B, Ramió-Torrentà L, Eichau Madueño S, Gascón-Giménez F, Casanova B, Martínez-Yélamos S, Aguado Valcárcel M, Martínez Ginés ML, El Berdei Montero Y, López Real AM, González-Quintanilla V, De Torres L, Martínez-Rodríguez JE, Costa-Frossard L, Garcés Redondo M, Labiano Fontcuberta A, Castellanos-Pinedo F, García Merino JA, Muñoz Fernández C, Castillo-Triviño T, Meca-Lallana V, Peña Martínez J, Rodríguez-Antigüedad A, Prieto González JM, Agüera Morales E, Pérez Molina I, Solar Sánchez DM, Herrera Varo N, Romero Sevilla R, Gómez Vicente L, Río J. Oreja-Guevara C, et al. Among authors: meca lallana je. Mult Scler Relat Disord. 2024 Oct;90:105787. doi: 10.1016/j.msard.2024.105787. Epub 2024 Aug 2. Mult Scler Relat Disord. 2024. PMID: 39142050 Free article.
Does serum neurofilament light chain measurement influence therapeutic decisions in multiple sclerosis?
Saposnik G, Monreal E, Medrano N, García-Domínguez JM, Querol L, Meca-Lallana JE, Landete L, Salas E, Meca-Lallana V, García-Arcelay E, Agüera-Morales E, Martínez-Yélamos S, Gómez-Ballesteros R, Maurino J, Villar LM, Caminero AB. Saposnik G, et al. Among authors: meca lallana je. Mult Scler Relat Disord. 2024 Oct;90:105838. doi: 10.1016/j.msard.2024.105838. Epub 2024 Aug 23. Mult Scler Relat Disord. 2024. PMID: 39216454
Beyond lines of treatment: embracing early high-efficacy disease-modifying treatments for multiple sclerosis management.
Oreja-Guevara C, Martínez-Yélamos S, Eichau S, Llaneza MÁ, Martín-Martínez J, Peña-Martínez J, Meca-Lallana V, Alonso-Torres AM, Moral-Torres E, Río J, Calles C, Ares-Luque A, Ramió-Torrentà L, Marzo-Sola ME, Prieto JM, Martínez-Ginés ML, Arroyo R, Otano-Martínez MÁ, Brieva-Ruiz L, Gómez-Gutiérrez M, Rodríguez-Antigüedad A, Galán Sánchez-Seco V, Costa-Frossard L, Hernández-Pérez MÁ, Landete-Pascual L, González-Platas M, Meca-Lallana JE. Oreja-Guevara C, et al. Among authors: meca lallana je. Ther Adv Neurol Disord. 2024 Oct 16;17:17562864241284372. doi: 10.1177/17562864241284372. eCollection 2024. Ther Adv Neurol Disord. 2024. PMID: 39483817 Free PMC article. Review.
Investigating the 2023 MOGAD Criteria in Children and Adults With MOG-Antibody Positivity Within and Outside Attacks.
Fonseca E, Olivé-Cirera G, Martinez-Hernandez E, Guasp M, Naranjo L, Ruiz-García R, Caballero E, González-Álvarez V, Delgadillo V, Romeu G, Del-Prado-Sánchez C, Cabrera-Maqueda JM, Benito-León J, Iñiguez C, Garcia-Dominguez JM, Calles C, Cano A, Álvarez-Bravo G, González-Suárez I, Oreja-Guevara C, Ros M, Millan-Pascual J, Meca-Lallana JE, Borrega Canelo L, Martín-Martínez J, Palao M, Gracia J, Villaverde-González R, Llufriu S, Blanco Y, Saiz A, Dalmau J, Sepulveda M, Armangue T; Spanish MOGAD study group. Fonseca E, et al. Among authors: meca lallana je. Neurology. 2024 Sep 24;103(6):e209682. doi: 10.1212/WNL.0000000000209682. Epub 2024 Aug 27. Neurology. 2024. PMID: 39190859
Profile and Usefulness of Serum Cytokines to Predict Prognosis in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
Villacieros-Álvarez J, Espejo C, Arrambide G, Dinoto A, Mulero P, Rubio-Flores L, Nieto P, Alcalá C, Meca-Lallana JE, Millan-Pascual J, Martínez-García P, Bernard-Valnet R, González-Suárez I, Orviz A, Téllez R, Navarro Cantó L, Presas-Rodríguez S, Martínez-Yélamos S, Cuello JP, Alonso A, Piñar Morales R, Álvarez Bravo G, Benyahya L, Trouillet-Assant S, Dyon-Tafan V, Froment Tilikete C, Ruet A, Bourre B, Deschamps R, Papeix C, Maillart E, Kerschen P, Ayrignac X, Rovira À, Auger C, Audoin B, Montalban X, Tintore M, Mariotto S, Cobo-Calvo A, Marignier R. Villacieros-Álvarez J, et al. Among authors: meca lallana je. Neurol Neuroimmunol Neuroinflamm. 2025 Mar;12(2):e200362. doi: 10.1212/NXI.0000000000200362. Epub 2025 Jan 3. Neurol Neuroimmunol Neuroinflamm. 2025. PMID: 39752619 Free PMC article.
86 results